Larivière M, Beauvais B, Aziz M, Garin J F, Abeloos J, Derouin F, Bamba M, Bossebceuf C, Ferly-Therizol M, Sarfati C
Faculté de Medecine Lariboisière-Saint-Louis, Laboratoire de Parasitologie-Mycologie, Paris, France.
Bull Soc Pathol Exot Filiales. 1989 Jan;82(1):35-47.
Two hundred and twenty adult males living in endemic onchocerciasis areas in Ivory Coast, with a mean of 59 to 64 mf/mg of skin microfilariae, having or not ocular lesions, were divided into 4 homogeneous groups and treated by placebo or by a single oral dose of 100, 150 or 200 mcg/kg of ivermectin. Parasitological, clinical, ophthalmological, biological data were gathered before treatment (J less than 1) and at day 4 and 3, 6, 12 months post treatment. The doses of 150 to 200 mcg/kg gave the best results with a reduction of microfilariae of 75 to 79% at day 4 and of 97 to 99% at 3 months. A slight increase appears at six months reaching to 10% of the initial level, at 12 months. These posologies reduce also the number of ocular microfilariae 12 months after treatment. The percentage of patients presenting microfilariae in the cornea varies from 4 to 14% according to the given dose whereas it was initially between 26 and 33%, and in the anterior chamber from 22 to 16% instead of 62 to 67%. In patients who were still positive after treatment the detected number of ocular microfilariae was very small. Side effects starting 12 to 24 hours after treatment are similar to those appearing during the normal evolution of onchocerciasis. They were observed in 36% of subjects receiving a placebo and 56 to 65% of treated subjects. Statistically they are neither correlated with the intensity of parasitism nor to the given posology and disappear spontaneously few days later or after administration of aspirin and/or antihistaminic. Ivermectin given at a single oral dosage of 150 to 200 mcg/kg is a powerful microfilaricidal drug with a rapid and prolonged action and without major side effects.
220名居住在科特迪瓦盘尾丝虫病流行区的成年男性,皮肤微丝蚴平均密度为59至64条/毫克,有或无眼部病变,被分为4个同质组,分别接受安慰剂或单次口服100、150或200微克/千克的伊维菌素治疗。在治疗前(J小于1)以及治疗后第4天和第3、6、12个月收集寄生虫学、临床、眼科和生物学数据。150至200微克/千克的剂量效果最佳,治疗后第4天微丝蚴减少75%至79%,3个月时减少97%至99%。6个月时略有增加,到12个月时达到初始水平的10%。这些剂量在治疗12个月后也减少了眼部微丝蚴的数量。角膜中有微丝蚴的患者百分比根据给药剂量从4%至14%不等,而初始时为26%至33%,前房中的百分比从22%降至16%,而不是62%至67%。治疗后仍呈阳性的患者中,检测到的眼部微丝蚴数量非常少。治疗后12至24小时开始出现的副作用与盘尾丝虫病正常病程中出现的副作用相似。在接受安慰剂的受试者中有36%观察到这些副作用,在接受治疗的受试者中有56%至65%观察到。从统计学上看,它们既与寄生虫感染强度无关,也与给药剂量无关,几天后或服用阿司匹林和/或抗组胺药后会自行消失。单次口服剂量为150至200微克/千克的伊维菌素是一种强效杀微丝蚴药物,作用迅速且持久,无重大副作用。